Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease

Authors:

Abstract
Stem cell therapy is a promising approach for the treatment of tissue ischemia associated with myocardial infarction and peripheral arterial disease. Stem and progenitor cells derived from bone marrow or from pluripotent stem cells have shown therapeutic benefit in boosting angiogenesis as well as restoring tissue function. Notably, adult stem and progenitor cells including mononuclear cells, endothelial progenitor cells, and mesenchymal stem cells have progressed into clinical trials and have shown positive benefits. In this review, we overview the major classes of stem and progenitor cells, including pluripotent stem cells, and summarize the state of the art in applying these cell types for treating myocardial infarction and peripheral arterial disease.
Funding Information
  • Office of Extramural Research, National Institutes of Health (OER) (HL098688, EB020235, HL088957, HL089315, HL088957)
  • U.S. Department of Veterans Affairs (VA) (1I01BX002310)
  • Stanford Chemistry Engineering & Medicine for Human Health (grant)
  • Stanford Cardiovascular Institute (grant)
  • McCormick Gabilan Fellowship (grant)

This publication has 120 references indexed in Scilit: